Missed GME or NVDA? Don’t Miss the Next One.​
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PAVM Stock Forecast 2025-2026
$0.65
Current Price
$10.91M
Market Cap
Buy 2
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to PAVM Price Targets
+2,913.9%
To High Target of $19.50
+1,716.1%
To Median Target of $11.75
+518.2%
To Low Target of $4.00
PAVM Price Momentum
0.0%
1 Week Change
-13.3%
1 Month Change
-62.4%
1 Year Change
+3.2%
Year-to-Date Change
-65.9%
From 52W High of $1.90
+17.6%
From 52W Low of $0.55
📉 MARKET SELLOFF ALERT
10 Quality Stocks Worth Considering Now
Researching PAVmed (PAVM) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on PAVM and similar high-potential opportunities.
Latest PAVM Stock Price Targets & Analyst Predictions
Based on our analysis of 4 Wall Street analysts, PAVM has a bullish consensus with a median price target of $11.75 (ranging from $4.00 to $19.50). The overall analyst rating is Strong Buy (9.0/10). Currently trading at $0.65, the median forecast implies a 1,716.1% upside. This outlook is supported by 2 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward Woo at Ascendiant Capital, projecting a 2,913.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PAVM Analyst Ratings
2
Buy
0
Hold
0
Sell
PAVM Price Target Range
Low
$4.00
Average
$11.75
High
$19.50
Current: $0.65
Latest PAVM Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PAVM.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 21, 2025 | Ascendiant Capital | Edward Woo | Buy | Maintains | $19.50 |
| Dec 9, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $19.00 |
| Sep 10, 2024 | Ascendiant Capital | Edward Woo | Buy | Maintains | $21.00 |
| Aug 18, 2023 | Cantor Fitzgerald | Ross Osborn | Neutral | Reiterates | $1.40 |
| Jan 20, 2023 | Cantor Fitzgerald | Ross Osborn | Neutral | Downgrade | $1.50 |
| Jan 18, 2023 | Lake Street | Frank Takkinen | Buy | Maintains | $1.50 |
| Aug 17, 2022 | Lake Street | Frank Takkinen | Buy | Maintains | $5.00 |
| Mar 30, 2021 | Cantor Fitzgerald | Overweight | Initiates | $0.00 | |
| Nov 5, 2020 | Ascendiant Capital | Buy | Initiates | $0.00 | |
| Oct 13, 2020 | Lake Street | Buy | Initiates | $0.00 | |
| Jun 28, 2018 | Maxim Group | Buy | Initiates | $0.00 |
PAVmed Inc. (PAVM) Competitors
The following stocks are similar to PAVmed based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PAVmed Inc. (PAVM) Financial Data
PAVmed Inc. has a market capitalization of $10.91M with a P/E ratio of 0.2x. The company generates $3.00M in trailing twelve-month revenue with a 1,328.6% profit margin.
Revenue growth is -99.0% quarter-over-quarter, while maintaining an operating margin of -51,870.0% and return on equity of -454.5%.
Valuation Metrics
Market Cap
$10.91M
Enterprise Value
$39.68M
P/E Ratio
0.2x
PEG Ratio
-0.4x
Price/Sales
3.6x
Growth & Margins
Revenue Growth (YoY)
-99.0%
Gross Margin
-350.0%
Operating Margin
-51,870.0%
Net Margin
+1,328.6%
EPS Growth
-99.2%
Financial Health
Cash/Price Ratio
+14.1%
Current Ratio
0.1x
Debt/Equity
0.8x
ROE
-454.5%
ROA
-87.2%
💰 DON'T MISS THIS OPPORTUNITY
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
PAVmed Inc. (PAVM) Business Model
About PAVmed Inc.
What They Do
Develops innovative medical devices and technologies.
Business Model
PAVmed Inc. operates by developing a diverse range of medical devices and healthcare technologies aimed at fulfilling unmet medical needs. The company generates revenue through the commercialization of its products, which include advanced diagnostic tools and biomaterials, allowing it to capitalize on high-growth sectors within the healthcare market.
Additional Information
Headquartered in New York, PAVmed is strategically positioned to impact the medical device market significantly. Its subsidiaries, such as Lucid Diagnostics and Solys, enhance its product portfolio, focusing on minimally invasive solutions that improve patient care across various medical domains.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
39
CEO
Dr. Lishan Aklog M.D.
Country
United States
IPO Year
2016
Website
www.pavmed.comPAVmed Inc. (PAVM) Latest News & Analysis
Latest News
Quick Summary
PAVmed Inc. (NASDAQ:PAVM) will host its Q1 2025 Earnings Conference Call on May 15, 2025, at 8:30 AM ET, featuring key company executives and analysts from Maxim Group and Ascendiant Capital.
Why It Matters
PAVmed’s Q1 2025 earnings call indicates upcoming financial performance insights, critical for assessing the company’s growth prospects and potential investment value.
Source: Seeking Alpha
Market Sentiment:
Neutral
Quick Summary
PAVmed provided a business update, highlighting Lucid's secured funding for growth and Veris Health's financing to develop a physiological monitor. A conference call is scheduled for May 15, 2025.
Why It Matters
Lucid's capital securing extends its operational runway, enhancing growth potential. PAVmed's partnerships and asset evaluations signal strategic expansion in the medical sector, attracting investor interest.
Source: PRNewsWire
Market Sentiment:
Neutral
Lucid Diagnostics Provides Business Update and Reports First Quarter 2025 Financial Results
10 days ago
Quick Summary
Lucid Diagnostics processed 3,034 EsoGuard® tests, generating $0.8 million in revenue for Q1 2025. The company ended the quarter with over $40 million in cash and will hold a conference call today.
Why It Matters
Lucid Diagnostics' revenue growth and strong cash position signal operational stability and potential for future funding, crucial for meeting reimbursement milestones and sustaining investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Lucid Diagnostics Inc. will hold a business update conference call and webcast on May 14, 2025, at 8:30 AM ET, led by Dr. Lishan Aklog.
Why It Matters
Lucid Diagnostics' upcoming conference call may reveal key updates on business performance and strategic direction, influencing investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PAVmed Inc. will hold a business update conference call and webcast on May 15, 2025, at 8:30 AM ET. CEO Lishan Aklog will lead the discussion. (Nasdaq: PAVM, PAVMZ)
Why It Matters
PAVmed's upcoming conference call signals an opportunity for updates on business performance and strategic direction, which can influence investor sentiment and stock valuation.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PAVmed (PAVM) has been upgraded to a Zacks Rank #2 (Buy), indicating increased optimism about its earnings prospects, which may boost the stock price in the near term.
Why It Matters
PAVmed's Zacks Rank upgrade to #2 signals increased earnings optimism, potentially boosting investor interest and driving the stock price higher in the short term.
Source: Zacks Investment Research
Market Sentiment:
Positive
Frequently Asked Questions About PAVM Stock
What is PAVmed Inc.'s (PAVM) stock forecast for 2025?
Based on our analysis of 4 Wall Street analysts, PAVmed Inc. (PAVM) has a median price target of $11.75. The highest price target is $19.50 and the lowest is $4.00.
Is PAVM stock a good investment in 2025?
According to current analyst ratings, PAVM has 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $0.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PAVM stock?
Wall Street analysts predict PAVM stock could reach $11.75 in the next 12 months. This represents a 1,716.1% increase from the current price of $0.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is PAVmed Inc.'s business model?
PAVmed Inc. operates by developing a diverse range of medical devices and healthcare technologies aimed at fulfilling unmet medical needs. The company generates revenue through the commercialization of its products, which include advanced diagnostic tools and biomaterials, allowing it to capitalize on high-growth sectors within the healthcare market.
What is the highest forecasted price for PAVM PAVmed Inc.?
The highest price target for PAVM is $19.50 from Edward Woo at Ascendiant Capital, which represents a 2,913.9% increase from the current price of $0.65.
What is the lowest forecasted price for PAVM PAVmed Inc.?
The lowest price target for PAVM is $4.00 from at , which represents a 518.2% increase from the current price of $0.65.
What is the overall PAVM consensus from analysts for PAVmed Inc.?
The overall analyst consensus for PAVM is bullish. Out of 4 Wall Street analysts, 2 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $11.75.
How accurate are PAVM stock price projections?
Stock price projections, including those for PAVmed Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 24, 2025 3:58 AM UTC